Source link : https://www.newshealth.biz/health-news/novel-drug-effective-against-mash-in-phase-ii-trial/
An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic dysfunction-associated steatohepatitis (MASH) in a phase II clinical trial. In 168 patients with MASH and stage F2-F3 fibrosis randomized to a daily dose of denifanstat or placebo, 26% of those in the treatment group experienced MASH resolution at 52 weeks […]
Author : News Health
Publish date : 2024-10-14 18:25:39
Copyright for syndicated content belongs to the linked Source.
Categories